Navigation Links
China Sky One Medical Receives GMP Re-Certification
Date:5/27/2010

product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    China Sky One Medical, Inc.
     Mr. Stanley Hao, CFO
     Tel:   +86-451-8703-2617
     Email: stanleyhao@cski.com.cn

    Investor Relations Contact:
     CCG Investor Relations
     Ms. Lei Huang, Account Manager
     Tel:   +1-646-833-3417
     Email: lei.huang@ccgir.com

     Ms. Mabel Zhang, Vice President
     Tel:   +1-310-954-1353
     Email: mabel.zhang@ccgir.com
     Web:   http://www.ccgirasia.com


'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dehaier Medical Systems Continues Product Line Expansion. Signs Exclusive Distribution Agreement with HEYER Medical for Respiratory Products in China
2. China BCT Reports First Quarter 2010 Results
3. China-Biotics Provides Updates on Qingpu New Facility and Chinese Probiotics Market
4. OriGene Technologies, Inc. to Build the Worlds Largest TrueMAB(TM) Monoclonal Antibody Facility in Wuxi, China
5. China Biologic Products Schedules Conference Call to Discuss First Quarter 2010 Results
6. Renhuang Pharmaceuticals Exhibits All-Natural Products at the 63rd PHARMACHINA Fair
7. China Pharma Holdings, Inc. CEO to Speak at Brean Murray, Carret & Co. 2010 Life Sciences Summit
8. China Sky One Medical Provides Sales Forecast for 13 New Products
9. China Sky One Medical Attended Import and Export Fair to Enhance International Growth Opportunity
10. Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd.
11. China Pharma Holdings, Inc. Reports First Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... ... supplier, announces the launch of their 2nd generation cell therapy POD® design. The ... CT, but it also represents a new POD® design. , “G-CON first ...
(Date:7/29/2015)... 2015  AmnioChor Inc., an early stage biotech startup ... to announce that the Musculoskeletal Transplant Foundation of ... in their seed round of development of the proprietary ... AmnioChor,s technology allows cryopreservation of the ... cells living within those tissues. Amnion is a well-established ...
(Date:7/29/2015)... 2015  Indivior PLC (LON: INDV) today announced that ... was accepted and received Priority Review by the U.S. ... opioid overdose. This naloxone nasal spray comes as a ... absorption into the nasal mucosa. 1 The device ... may be better equipped to help an opioid overdose ...
(Date:7/29/2015)... QUEBEC CITY , July 29, 2015 /PRNewswire/ ... (the "Company") today announced it has selected an optimized ... important milestone in the development of a new ... The MAPK pathway represents a prime target for ... significant antitumor activities and survival benefits for B-Raf ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... N.J., June 23 SyntheMed, Inc. (OTC Bulletin Board: ... commercialization of anti-adhesion products, announced today that the company ... Health Innovation Award in pediatrics. The company ... & Sullivan medical device analysts in recognition of the ...
... CHICAGO, June 23 Advanced Life Sciences Holdings, Inc. ... non-human primate study involving its novel, once-a-day, oral antibiotic ... achieved a 100% survival rate against an inhaled lethal ... study that received 16 mg/kg once-a-day (the human equivalent ...
... to Double 2009 Grant Awards to Nearly $4 Million ... The Lustgarten Foundation, the nation,s largest private supporter of pancreatic ... totaling $1.6 million awarded to six leading research centers for ... nation,s deadliest cancers. , , Lustgarten is expected ...
Cached Biology Technology:SyntheMed Receives Frost & Sullivan Health Innovation Award Nomination 2Advanced Life Sciences' Restanza(TM) Shows 100% Survival In Confirmatory Anthrax Study 2Advanced Life Sciences' Restanza(TM) Shows 100% Survival In Confirmatory Anthrax Study 3The Lustgarten Foundation Awards Six Research Centers With Pancreatic Cancer Research Funding 2
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION ... new convenient and secure method to make payments.  ... payment methods, introduced with its groundbreaking voice-direct payment ...
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
(Date:7/7/2015)... , July 7, 2015  Based on ... Frost & Sullivan recognizes Credence ID, LLC with ... Entrepreneurial Company of the Year Award. Credence ID ... aid in its mission of offering enrollment and ... globally. As Credence ID was formed by experts ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... weekend warriors: the simple act of exercise and not ... a new University of Florida study finds. People ... gaining strength or boosting cardiovascular fitness feel just as ... said Heather Hausenblas, a UF exercise psychologist. Her study ...
... sees the launch of Ensembl Plants a ... by the European Molecular Biology Laboratory,s European ... Spring Harbor Laboratory, USA. Ensembl Plants allows researchers ... genome-scale experiments in different plant species. By pinpointing ...
... disease and other diet related health problems received a 4 ... projects. The projects, taking place in universities and research institutes ... publicly-funded Research Councils and 15 companies. This means the research ... in our society but in a way that the food ...
Cached Biology News:UF study: Exercise improves body image for fit and unfit alike 2UF study: Exercise improves body image for fit and unfit alike 3New portal for plant genomics will support research into improved crops 2Public sector and industry unite to attack obesity and heart disease 2
... Rabbit polyclonal to Ki67 - Proliferation Marker, ... cell cycle related nuclear protein, expressed by ... active cell cycle (G1, S, G2 and ... (G0) cells. Ki67 antibodies are useful in ...
Rabbit polyclonal to Shigella (HRP) ( Abpromise for all tested applications)....
HLA II DG+DR+DP Monoclonal Antibody, Purified, Unconjugated, Clone: IQU9 This antibody is specific for the monomorphic determinant of the HLA Class II beta chains of the human MHC (28 kDa)....
100 g monoclonal antibody which can immunocapture ~10 g of Complex IV from heart mitochondria. Also included are 2 mg of bovine heart mitochondria for control immunocapture....
Biology Products: